A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma (NCT02718833)

🧪 Interventions in This Study

• Elotuzumab (DRUG)
• Pomalidomide (DRUG)
• Bortezomib (DRUG)
• Dexamethasone (DRUG)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. All laboratory assessments should be performed within 21 days of initiation of protocol therapy unless otherwise specified.
2. Participant has given voluntary signed written informed consent before performance of any study-related procedure that is not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to their future medical care.
3. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (see Appendix A).
4. Age ≥ 18 years
5. Measurable disease of multiple myeloma as defined by at least one of the following
6. Serum monoclonal protein ≥ 0.5 g/dL
7. ≥ 200 mg of monoclonal protein in the urine on 24 hour electrophoresis
8. Serum free light chain ≥ 100 mg/L (10 mg/dL) and abnormal serum free kappa to serum free kappa light chain ratio
9. Previously treated relapsed and refractory multiple myeloma
10. Patients must have received at least one prior therapy with at least 2 cycles of lenalidomide and at least 2 cycles of a proteasome inhibitor (either in separate regimens or within the same regimen)
11. Disease progression on or within 60 days of completion of last therapy.
12. ANC ≥ 1000/μL. G-CSF is not permitted within 14 days of screening.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (6 Sites)

• Massachusetts General Hospital Cancer Center — Boston, Massachusetts
• Dana-Farber Cancer Institute — Boston, Massachusetts
• Mass General/North Shore Cancer Center — Danvers, Massachusetts
• Newton-Wellesley Hospital — Newton, Massachusetts
• University of Michigan — Ann Arbor, Michigan
• University of Rochester — Rochester, New York

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Multiple Myeloma

• Registry for Adults With Plasma Cell Disorders (PCD's) — Chapel Hill, North Carolina
• A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma — Mobile, Alabama
• A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events — San Francisco, California
• A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients — Goodyear, Arizona
• Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study) — Miami, Florida
• Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma — La Crosse, Wisconsin

Explore by condition: All Multiple Myeloma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.